AMYLYX PHARMACEUTICALS INC (AMLX) Stock Analyst Earnings Estimates
NASDAQ:AMLX - Nasdaq - US03237H1014 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 290K -55.38% | 22.23M 7,565.52% | 380.786M 1,612.94% | 89.575M -76.48% | -100.00% | 328.95K | 3.229M 881.61% | 22.291M 590.34% | 70.071M 214.35% | 120.56M 72.05% | 171.74M 42.45% | 239.14M 39.25% | |
| EBITDA YoY % growth | -82.64M -111.84% | -200.85M -143.04% | 39.89M 119.86% | -317.404M -895.70% | -132.457M 58.27% | -235.253M -77.61% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -82.69M -111.97% | -201.34M -143.49% | 38.802M 119.27% | -318.699M -921.35% | -136.6M 57.14% | -138.695M -1.53% | -74.136M 46.55% | -55.551M 25.07% | -41.893M 24.59% | -15.535M 62.92% | 10.459M 167.33% | 58.199M 456.45% | |
| Operating Margin | -28,513.79% | -905.71% | 10.19% | -355.79% | N/A | -42,162.89% | -2,295.95% | -249.21% | -59.79% | -12.89% | 6.09% | 24.34% | |
| EPS YoY % growth | N/A | -3.43 -84.77% | 0.70 120.41% | -4.42 -731.31% | -1.69 61.74% | -1.63 3.87% | -1.02 37.24% | -0.83 19.00% | -0.67 18.52% | -0.54 19.70% | 0.33 161.32% | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.53 -857.71% | -0.63 -427.00% | -0.65 10.58% | -0.66 38.04% | -0.63 -19.23% |
| Revenue Q2Q % growth | -100.00% | -100.00% | 100.00% | -100.00% | 45.492M |
| EBITDA Q2Q % growth | -44.268M -1,564.86% | -39.27M -33.96% | -35.088M 33.69% | -32.844M 15.16% | -31.926M 27.88% |
| EBIT Q2Q % growth | -39.707M -2,153.11% | -46.022M -55.32% | -46.942M 12.15% | -47.882M -21.35% | -48.84M -23.00% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -1.07 -456.67% | -0.72 | -0.35 | -47.75% |
| Q2 2024 Q2Q % growth | -0.73 -335.48% | -0.74 | 0.01 | 1.96% |
| Q1 2024 Q2Q % growth | -0.12 -700.00% | -0.01 | -0.11 | -1,860.78% |
| Q4 2023 Q2Q % growth | 0.07 110.77% | 0.23 | -0.16 | -69.94% |
| Q3 2023 Q2Q % growth | 0.30 132.61% | 0.44 | -0.14 | -32.39% |
| Q2 2023 Q2Q % growth | 0.31 133.33% | 0.10 | 0.21 | 203.92% |
| Q1 2023 Q2Q % growth | 0.02 102.15% | -0.25 | 0.27 | 108.15% |
| Q4 2022 Q2Q % growth | -0.65 84.34% | -0.84 | 0.19 | 22.25% |
| Q3 2022 Q2Q % growth | -0.92 | -0.99 | 0.07 | 7.16% |
| Q2 2022 Q2Q % growth | -0.93 | -0.89 | -0.04 | -4.50% |
| Q1 2022 Q2Q % growth | -0.93 | -0.70 | -0.23 | -32.78% |
| Q4 2021 Q2Q % growth | -4.15 | -0.65 | -3.50 | -535.72% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 416K -99.59% | 416K | % | |
| Q2 2024 Q2Q % growth | -1.023M -101.04% | 10.876M | -11.899M | -109.41% |
| Q1 2024 Q2Q % growth | 88.643M 24.10% | 100.31M | -11.667M | -11.63% |
| Q4 2023 Q2Q % growth | 108.449M 395.20% | 109.1M | -651K | -0.60% |
| Q3 2023 Q2Q % growth | 102.693M 34,131.00% | 115.93M | -13.237M | -11.42% |
| Q2 2023 Q2Q % growth | 98.216M | 93.98M | 4.236M | 4.51% |
| Q1 2023 Q2Q % growth | 71.428M | 60.167M | 11.261M | 18.72% |
| Q4 2022 Q2Q % growth | 21.9M | 4.82M | 17.08M | 354.36% |
| Q3 2022 Q2Q % growth | 300K | 84.997K | 215.003K | 252.96% |
| Q2 2022 Q2Q % growth | 84.997K | -84.997K | -100.00% | |
| Q1 2022 Q2Q % growth | 84.997K | -84.997K | -100.00% | |
| Q4 2021 Q2Q % growth | -100.00% | 729.3K | -729.3K | -100.00% |
| Q3 2021 Q2Q % growth | 300K | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 3.7% | 3.7% | 0% | -2.18% |
| Revenue | N/A | N/A | -0.13% | 0.24% |